The Never-Ending Date

Daniel Paul Shear stopped at a red light in North Hollywood, Calif., in 2017 long enough to snap a photo of the Idle Hour bar, a building in the shape of a whiskey barrel, to send to Nora Charlotte Tillmanns. “I’m a native Angelino and I love fun design,” said Ms. Tillmanns, 32, who got…

Details

COVID-19 morbidity and mortality in people with rheumatic diseases

Arani Vivekanantham and colleagues investigated the association between RA and the risk of COVID-19 diagnosis, hospitalization with COVID-19,and COVID-19-related death. This population-based cohort study including all individuals registered in the Information System for Research in Primary Care (SIDIAP)- which covers over80% of the population of Catalonia, Spain. This information was linked to region-wide SARS-CoV-2 testing,…

Details

The true spread of SARS-CoV-2 infection is much greater than that observed by capturing only swab-diagnosed COVID-19 cases

As part of the MAINSTREAM project, Favalli and colleagues conducted a seroprevalence cross-sectional study between 4th May and 16th June 2020toestimate the prevalence of anti-SARS-CoV-2 antibodies in a large cohort of people with rheumatoid arthritis (RA) or spondyloarthritis (SpA) treated with biologic or targeted synthetic disease modifying anti rheumatic drugs (b/tsDMARDs) in a COVID-19 high-endemic…

Details

Researchers find losartan is not effective in reducing hospitalization from mild COVID-19

MINNEAPOLIS/ST. PAUL (06/18/2021) — University of Minnesota Medical School researchers determined that the common blood pressure medication, losartan, is not effective in reducing hospitalization for mildly-ill COVID-19 outpatients. In the multicenter, randomized, double-blinded clinical trial, non-hospitalized patients recently diagnosed with COVID-19 were given either losartan or a placebo and monitored for 15 days. The study’s…

Details